Abstract
References
- 1. McLernon et al., 2016). McLernon DJ1, Maheshwari A2, Lee AJ2, Bhattacharya S2. Cumulative live birth rates after one or more complete cycles of IVF: a population-based study of linked cycle data from 178,898 women. Hum Reprod. 2016 Mar;31(3):572-81. doi: 10.1093/humrep/dev336. Epub 2016 Jan 18. 2. Goud AP, Goud PT, Diamond MP, Gonik B & Abu-Soud HM 2008 Reactive oxygen species and oocyte aging: Role of superoxide, hydrogenperoxide, and hypochlorousacid. Free Radical Biology and Medicine 441295–1304. 3. Zhang X, Li X-H, Ma X, Wang Z-H, Lu S &Guo Y-L 2006 Redox-induce apoptosis of human oocytes in resting follicles in vitro. Journal of the Society for Gynecologic Investigation 13 451–458. 4. Fernando S, Osianlis T, Vollenhoven B, Wallace E, Rombauts L. A pilot double-blind randomised placebo-controlled dose-response trial assessing the effects of melatonin on infertility treatment (MIART): study protocol. BMJ Open (2014) 4:e005986. doi: 10.1136/bmjopen-2014-005986 5. Bender DA Biochemistry of tryptophan in health and disease. Mol Aspects Med 1983;6:101–97. 6. Dubocovich M, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27:101–110. doi: 10.1385/ENDO:27:2:101. [PubMed] [CrossRef] [Google Scholar] 7. Tamura H, Takasaki A, Taketani T, Tanabe M, Kizuka F, Lee L, Tamura I, Maekawa R, Aasada H, Yamagata Y, Sugino N: The role of melatonin as an antioxidant in the follicle.J Ovarian Res 2012, 5.. ., [http://www.ovarianresearch.com/content/5/1/5] [PMC free article] [PubMed] 8. Tan D, Manchester L, Reiter R, Qi W, Karbownik M, Calvo J. Significance of melatonin in antioxidative defense system: reactions and products. Biol Signals Recept. 2000;9:137–159. doi: 10.1159/000014635. [PubMed] [CrossRef] [Google Scholar] 9. Acuña-Castroviejo D, Reiter R, Menéndez-Peláez A, Pablos M, Burgos A. Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver. J Pineal Res. 1994;16:100–112. doi: 10.1111/j.1600-079X.1994.tb00089.x. [PubMed] [CrossRef] [Google Scholar] 10. Benítez-King G, Huerto-Delgadillo L, Antón-Tay F. Binding of 3H-melatonin to calmodulin. Life Sci. 1993;53:201–207. doi: 10.1016/0024-3205(93)90670-X. [PubMed] [CrossRef] [Google Scholar] 11. Mayo J, Sainz R, Antoli I, Herrera F, Martin V, Rodriguez C. Melatonin regulation of antioxidant enzyme gene expression. Cell Moll Life Sci. 2002;59:1706–1713. doi: 10.1007/PL00012498. [PubMed] [CrossRef] [Google Scholar] 12. Boczek-Leszczyk E, Juszczak M. The influence of melatonin on human reproduction. Pol Merkur Lekarski. 2007;23:128–130. [PubMed] [Google Scholar] 13. Nakamura Y, Tamura H, Takayama H, Kato H. Increased endogenous level of melatonin in preovulatory human follicles does not directly influence progesterone production. Fertil Steril. 2003;80:1012–1016. doi: 10.1016/S0015-0282(03)01008-2. [PubMed] [CrossRef] [Google Scholar] 14. Wurtman R, Axelrod J, Potter L. The uptake of h3-melatonin in endocrine and nervous tissues and the effects of constant light exposure. J Pharmacol Exp Ther. 1964;143:314–318. [PubMed] [Google Scholar] 15. Knapen M, Zusterzeel P, Peters W, Steegers E. Glutathione and glutathione-related enzymes in reproduction: a review. Eur J Obstet Gynecol Reprod Biol. 1999;82:171–184. doi: 10.1016/S0301-2115(98)00242-5. [PubMed] [CrossRef] [Google Scholar] 16. Rizzo P, Raffone E, Benedetto V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci 2010;14:555–561 17. Tamura H, Takasaki A, Miwa I, Taniguchi K, Maekawa R, Asada H. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. J Pineal Res 2008;44:280–287. 18. Shavi Fernando,1,2,* Euan Morrison Wallace,1,2 Beverley Vollenhoven,1,3 Nicholas Lolatgis,3 Nicole Hope,3 Melissa Wong,3 Mark Lawrence,3 Anthony Lawrence,3 Chris Russell,3 Kenneth Leong,3 Philip Thomas,3 and Luk Rombauts1,3. Melatonin in Assisted Reproductive Technology: A Pilot Double-Blind Randomized Placebo-Controlled Clinical Trial. Front Endocrinol (Lausanne). 2018; 9: 545. 19. Jing Tong1,2, Shile Sheng3, Yun Sun1,2, Huihui Li1,2,4, Wei-Ping Li1,2, Cong Zhang1,2,5and Zi-Jiang Chen1,2,6,7,8. Melatonin levels in follicular fluid as markers for IVF outcomes and predicting ovarian reserve. Reproduction (2017) 153 443–451. 20. S. Fernando1,3, L. Rombauts4,3, E. Wallace3, N. White2, J. Hong2, F. da Silva Costa2,3. The effect of melatonin on ultrasound markers of follicular development: a double-blind placebo-controlled randomised trial. Ultrasound in Obstetrics & Gynecology 2017; 50 (Suppl. 1): 1–47. 21. Fernando S, Biggs SN, Horne RSC, Vollenhoven B, Lolatgis N, Hope N, et al. The impact of melatonin on the sleep patterns of women undergoing IVF: a double blind RCT. Hum Reprod Open (2017) 2017: hox027 10.1093/hropen/hox027 [CrossRef] [Google Scholar] 22. Showell M, Brown J, Clarke J, Hart R: Antioxidants for female subfertility.Cochrane Database Syst Rev 2013. [PubMed] 23. Maestroni GJ, Cardinali DP, Esquifino AI, Pandi-Perumal SR. Does melatonin play a disease-promoting role in rheumatoid arthritis? J Neuroimmunol. 2005;158:106–111. doi: 10.1016/j.jneuroim.2004.08.015. [PubMed] [CrossRef] [Google Scholar] 24. Hong YG, Riegler JL. Is melatonin associated with the development of autoimmune hepatitis? J Clin Gastroenterol. 1997;25:376–378. doi: 10.1097/00004836-199707000-00020. [PubMed] [CrossRef] [Google Scholar] 25. Constantinescu CS. Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis. Med Hypotheses. 1995;45:455–458. doi: 10.1016/0306-9877(95)90220-1. [PubMed] [CrossRef] [Google Scholar]
Abstract
Aims: Melatonin is the most powerful antioxidant and protects sperm, oocyte and embryo against oxidative stress. The effect of tryptophan, which is the building block of melatonin, on follicular melatonin levels and IVF outcomes is unknown. The objective of this study was to investigate the effect of tryptophan administration, a precursor for melatonin, on the levels of intrafollicular melatonin with the aim to reveal the correlation between tryptophan and the total number and quality of oocytes as well as clinical pregnancy rates. In addition, we aimed to examine the effect of melatonin increased by tryptophan on uterine and ovarian blood flow.
Methods: Out of 103 patients who applied to Ondokuzmayis University IVF clinic for IVF treatment, 51 patients were administered a 100 mg dose of tryptophan orally (Group A) and 50 control patients who were randomly selected did not receive tryptophan (Group B). Firstly, follicular melatonin levels were compared between Group A receiving tryptophan and Group B without tryptophan. Both groups were also compared according to the oocyte count, oocyte count, fertilized oocyte count, embryo count and pregnancy rates, ultimately. In addition, all patients were measured for uterine and ovarian artery blood flow by vaginal ultrasound on the day of OPU..
Results: There were no differences in age (32.16 ± 3.82 years vs 33.06 ± 4.44 years) (p = 0.276), BMI (28.45 ± 2.82 kg/m)2 vs 28.15 ± 3.03kg/m2 (p = 0.602) and peak estradiol levels (2451.69 ± 469.75 pg/ml vs 2420.26 ± 443.71 pg / ml) (p = 0.73) between the groups. Group A exhibited high levels of melatonin in the follicular fluid with a mean value of 259.8 pg/ml, whereas Group B had 91.3 pg/ml (p <0.001). There were found significant differences in the oocyte count (9.08 ± 3.22 vs 7.66 ± 1.89) (p = 0,008), mature oocyte count (7.2 ± 2.8 vs 6.1 ± 1.8) (p = 0,021) and fertilized oocyte count (6.35 ± 2.44 vs 5.28 ± 1.69) between group A and group B. Pregnancy rates were higher in group A (35.3%). The pregnancy rate (30%) was lower in Group B, which did not receive tryptophan and had low melatonin levels in follicular fluid. However, there was no statistically significant difference. Uterine, ovarian artery systolic and diastolic blood flows of Group A were significantly lower than Group B (P <0.001).
Conclusions: Administration of tryptophan to IVF patients significantly increases the level of melatonin in follicular fluid. The results demonstrate that high levels of melatonin in follicular fluid may increase oocyte count and quality although they do not significantly improve clinical pregnancy rates.
Keywords
References
- 1. McLernon et al., 2016). McLernon DJ1, Maheshwari A2, Lee AJ2, Bhattacharya S2. Cumulative live birth rates after one or more complete cycles of IVF: a population-based study of linked cycle data from 178,898 women. Hum Reprod. 2016 Mar;31(3):572-81. doi: 10.1093/humrep/dev336. Epub 2016 Jan 18. 2. Goud AP, Goud PT, Diamond MP, Gonik B & Abu-Soud HM 2008 Reactive oxygen species and oocyte aging: Role of superoxide, hydrogenperoxide, and hypochlorousacid. Free Radical Biology and Medicine 441295–1304. 3. Zhang X, Li X-H, Ma X, Wang Z-H, Lu S &Guo Y-L 2006 Redox-induce apoptosis of human oocytes in resting follicles in vitro. Journal of the Society for Gynecologic Investigation 13 451–458. 4. Fernando S, Osianlis T, Vollenhoven B, Wallace E, Rombauts L. A pilot double-blind randomised placebo-controlled dose-response trial assessing the effects of melatonin on infertility treatment (MIART): study protocol. BMJ Open (2014) 4:e005986. doi: 10.1136/bmjopen-2014-005986 5. Bender DA Biochemistry of tryptophan in health and disease. Mol Aspects Med 1983;6:101–97. 6. Dubocovich M, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27:101–110. doi: 10.1385/ENDO:27:2:101. [PubMed] [CrossRef] [Google Scholar] 7. Tamura H, Takasaki A, Taketani T, Tanabe M, Kizuka F, Lee L, Tamura I, Maekawa R, Aasada H, Yamagata Y, Sugino N: The role of melatonin as an antioxidant in the follicle.J Ovarian Res 2012, 5.. ., [http://www.ovarianresearch.com/content/5/1/5] [PMC free article] [PubMed] 8. Tan D, Manchester L, Reiter R, Qi W, Karbownik M, Calvo J. Significance of melatonin in antioxidative defense system: reactions and products. Biol Signals Recept. 2000;9:137–159. doi: 10.1159/000014635. [PubMed] [CrossRef] [Google Scholar] 9. Acuña-Castroviejo D, Reiter R, Menéndez-Peláez A, Pablos M, Burgos A. Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver. J Pineal Res. 1994;16:100–112. doi: 10.1111/j.1600-079X.1994.tb00089.x. [PubMed] [CrossRef] [Google Scholar] 10. Benítez-King G, Huerto-Delgadillo L, Antón-Tay F. Binding of 3H-melatonin to calmodulin. Life Sci. 1993;53:201–207. doi: 10.1016/0024-3205(93)90670-X. [PubMed] [CrossRef] [Google Scholar] 11. Mayo J, Sainz R, Antoli I, Herrera F, Martin V, Rodriguez C. Melatonin regulation of antioxidant enzyme gene expression. Cell Moll Life Sci. 2002;59:1706–1713. doi: 10.1007/PL00012498. [PubMed] [CrossRef] [Google Scholar] 12. Boczek-Leszczyk E, Juszczak M. The influence of melatonin on human reproduction. Pol Merkur Lekarski. 2007;23:128–130. [PubMed] [Google Scholar] 13. Nakamura Y, Tamura H, Takayama H, Kato H. Increased endogenous level of melatonin in preovulatory human follicles does not directly influence progesterone production. Fertil Steril. 2003;80:1012–1016. doi: 10.1016/S0015-0282(03)01008-2. [PubMed] [CrossRef] [Google Scholar] 14. Wurtman R, Axelrod J, Potter L. The uptake of h3-melatonin in endocrine and nervous tissues and the effects of constant light exposure. J Pharmacol Exp Ther. 1964;143:314–318. [PubMed] [Google Scholar] 15. Knapen M, Zusterzeel P, Peters W, Steegers E. Glutathione and glutathione-related enzymes in reproduction: a review. Eur J Obstet Gynecol Reprod Biol. 1999;82:171–184. doi: 10.1016/S0301-2115(98)00242-5. [PubMed] [CrossRef] [Google Scholar] 16. Rizzo P, Raffone E, Benedetto V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci 2010;14:555–561 17. Tamura H, Takasaki A, Miwa I, Taniguchi K, Maekawa R, Asada H. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. J Pineal Res 2008;44:280–287. 18. Shavi Fernando,1,2,* Euan Morrison Wallace,1,2 Beverley Vollenhoven,1,3 Nicholas Lolatgis,3 Nicole Hope,3 Melissa Wong,3 Mark Lawrence,3 Anthony Lawrence,3 Chris Russell,3 Kenneth Leong,3 Philip Thomas,3 and Luk Rombauts1,3. Melatonin in Assisted Reproductive Technology: A Pilot Double-Blind Randomized Placebo-Controlled Clinical Trial. Front Endocrinol (Lausanne). 2018; 9: 545. 19. Jing Tong1,2, Shile Sheng3, Yun Sun1,2, Huihui Li1,2,4, Wei-Ping Li1,2, Cong Zhang1,2,5and Zi-Jiang Chen1,2,6,7,8. Melatonin levels in follicular fluid as markers for IVF outcomes and predicting ovarian reserve. Reproduction (2017) 153 443–451. 20. S. Fernando1,3, L. Rombauts4,3, E. Wallace3, N. White2, J. Hong2, F. da Silva Costa2,3. The effect of melatonin on ultrasound markers of follicular development: a double-blind placebo-controlled randomised trial. Ultrasound in Obstetrics & Gynecology 2017; 50 (Suppl. 1): 1–47. 21. Fernando S, Biggs SN, Horne RSC, Vollenhoven B, Lolatgis N, Hope N, et al. The impact of melatonin on the sleep patterns of women undergoing IVF: a double blind RCT. Hum Reprod Open (2017) 2017: hox027 10.1093/hropen/hox027 [CrossRef] [Google Scholar] 22. Showell M, Brown J, Clarke J, Hart R: Antioxidants for female subfertility.Cochrane Database Syst Rev 2013. [PubMed] 23. Maestroni GJ, Cardinali DP, Esquifino AI, Pandi-Perumal SR. Does melatonin play a disease-promoting role in rheumatoid arthritis? J Neuroimmunol. 2005;158:106–111. doi: 10.1016/j.jneuroim.2004.08.015. [PubMed] [CrossRef] [Google Scholar] 24. Hong YG, Riegler JL. Is melatonin associated with the development of autoimmune hepatitis? J Clin Gastroenterol. 1997;25:376–378. doi: 10.1097/00004836-199707000-00020. [PubMed] [CrossRef] [Google Scholar] 25. Constantinescu CS. Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis. Med Hypotheses. 1995;45:455–458. doi: 10.1016/0306-9877(95)90220-1. [PubMed] [CrossRef] [Google Scholar]
Details
| Primary Language | English |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Original Article |
| Authors | |
| Publication Date | March 19, 2020 |
| Published in Issue | Year 2020 Volume: 3 Issue: 2 |
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
|
|
|
| |
|
|
|
|
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
|
|
|
|
|
|
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Editor List for 2022
Assoc. Prof. Alpaslan TANOĞLU (MD)
Prof. Aydın ÇİFCİ (MD)
Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)
Prof. Murat KEKİLLİ (MD)
Prof. Yavuz BEYAZIT (MD)
Prof. Ekrem ÜNAL (MD)
Prof. Ahmet EKEN (MD)
Assoc. Prof. Ercan YUVANÇ (MD)
Assoc. Prof. Bekir UÇAN (MD)
Assoc. Prof. Mehmet Sinan DAL (MD)
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.